TreeFrog Therapeutics
Cell Therapy for All
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients.
TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality.
Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
TreeFrog Therapeutics I iPS-derived Cell Therapies I Cell Therapy for All
TreeFrog Therapeutics aims at making iPS-derived cell therapies safer, more efficient and more affordable to cure millions of patients.